Background: As physicians have increased opioid prescribing, overdose deaths from pharmaceutical opioids have substantially increased in the United States. Naloxone hydrochloride (naloxone), an opioid antagonist, is the standard of care for treatment of opioid induced respiratory depression. Since 1996, community-based programs have offered overdose prevention education and distributed naloxone for bystander administration to people who use opioids, particularly heroin. There is growing interest in translating overdose education and naloxone distribution (OEND) into conventional medical settings for patients who are prescribed pharmaceutical opioids. For this review, we summarized and classified existing publications on overdose education and naloxone distribution to identify evidence of effectiveness and opportunities for translation into conventional medical settings. Methods: For this review, we searched English language PubMed for articles on naloxone based on primary data collection from humans, including feasibility studies, program evaluations, surveys, qualitative studies, and studies comparing the effectiveness of different routes of naloxone administration. We also included cost-effectiveness studies. Results: We identified 41 articles that represented 5 categories: evaluations of OEND programs, effects of OEND programs on experiences and attitudes of participants, willingness of medical providers to prescribe naloxone, comparisons of different routes of naloxone administration, and the cost-effectiveness of naloxone. Conclusions: Existing research suggests that people who are at risk for overdose and other bystanders are willing and able to be trained to prevent overdoses and administer naloxone. Counseling patients about the risks of opioid overdose and prescribing naloxone is an emerging clinical practice that may reduce fatalities from overdose while enhancing the safe prescribing of opioids.
INTRODUCTION
Unintentional poisoning represents a significant, growing problem in the United States. [1] [2] [3] [4] [5] Drug poisoning fatalities now exceed deaths from motor vehicle crashes. 6 In 2010, opioid poisonings accounted for over 16,000 deaths. 7 Unintentional poisoning from pharmaceutical opioids has become an epidemic in the last decade, in part due to increasing opioid analgesic availability. 8 Overdose E. Harvard Ave., Suite 300, Denver, CO 80231, USA. E-mail: Shane.Mueller@kp.org Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/wsub.
SUBSTANCE ABUSE
FIGURE 1 PRISMA flowchart of included and excluded studies. 22 education and provision of naloxone is one approach to address this epidemic.
Naloxone is a short-acting opioid antagonist used by medical practitioners to reverse opioid overdose since 1971. In the United States, it is approved by the Food and Drug Administration (FDA) for prescription use. 9 Naloxone antagonizes opioid effects by displacing opioid agonists from opioid receptors in the central nervous system, reversing respiratory depression. Naloxone can be administered intranasally (IN), intramuscularly (IM), intravenously (IV), or subcutaneously and is effective against all opioid agonists, including morphine, heroin, oxycodone, and methadone. To reverse long-acting opioids, the dose may need to be repeated. The major adverse effect of naloxone in opioid-dependent patients is precipitated opioid withdrawal. This effect results from the rapid displacement of opioid agonist from the opioid receptor, the same mechanism by which naloxone also reverses respiratory depression. Naloxone has no psychoactive properties, is not a scheduled drug, and has no abuse potential. 10 Community-based and public health organizations have developed overdose education and naloxone distribution (OEND) programs to prevent opioid overdose fatalities among people who use heroin, and more recently, among people who use pharmaceutical opioids. In a survey of OEND programs completed in 2010, 188 programs located in 15 states and the District of Colombia provided take-home naloxone to people who used opioids. 11 From 1996 to 2010, these programs had trained and distributed naloxone to over 50,000 persons and received reports of over 10,000 overdose reversals. 11 Prevention strategies employed by these OEND programs may be applicable to the prevention of pharmaceutical opioid overdose deaths in primary care and specialty medical practices.
Provision of naloxone as a part of a strategy to address opioid overdose has been endorsed by several US Federal agencies. 12 In 2013, the Substance Abuse and Mental Health Services Administration released the Opioid Overdose Prevention Toolkit to provide communities and local governments information to develop policies to prevent opioid related deaths. 13 Scotland and Wales recently developed national naloxone distribution programs. 14 In early 2014, Norway began offering naloxone for the first time in intranasal form. 15 Other countries to allow for the distribution of naloxone include Sweden, 16 England, 17 Germany, 18 Italy, 19 Canada, 20 and Australia. 21 Conventional medical settings, such as primary care, pain clinics, emergency departments, and addiction treatment centers are potential venues for overdose education and naloxone prescription. These sites provide opioid prescriptions or medications and patients REVIEW 3 may present to these sites with complications from opioid use. Our aim was to review and classify existing publications on OEND and naloxone in community-based settings. We sought to identify evidence of effectiveness and opportunities for translation of these practices into conventional medical settings.
METHODS

Search Strategy and Article Selection
One author searched English language PubMed for peer-reviewed, original research articles through May 2014 using the following Medical Subject Heading (MeSH) terms: naloxone, drug overdose. This search yielded 254 articles. Two authors reviewed the abstracts of the 254 articles and excluded 221 articles because they were nonhuman studies, studies that did not focus on pre hospital-based administration of naloxone, efficacy studies in controlled settings, commentaries and perspectives, medical news articles, and policy or legal reviews. Based on the aim of our review to inform OEND programming in conventional medical settings, we included original peer-reviewed articles that involved primary data collection from patients or medical providers about OEND programs, including feasibility studies and program evaluations (if they included data collected from participants), surveys and qualitative studies of attitudes towards take-home naloxone, and studies comparing the effectiveness of different routes of naloxone administration in preand nonhospital settings. We also included cost-effectiveness studies. We also consulted national content experts and 3 of the authors searched the reference lists of the included articles, producing 7 additional articles that met inclusion criteria. A final consensus was reached by these 3 authors on the 41 articles included in this review. For reporting purposes, we then classified the articles into 5 major topic areas. A PRISMA diagram ( Figure 1 ) summarizes articles that were included in our initial search and were excluded based on our article selection criteria. 22 
Article Abstraction
Two of the authors reviewed each article and recorded the location, the number of participants, the population, the study design, the questions addressed by the article, and a summary of key findings. Given the early stage of research in this area and the heterogeneous methods and outcomes employed, we chose not to apply systematic methods, such as meta-analysis, to summarize outcomes.
RESULTS
We identified 41 articles that met our inclusion criteria (Table 1) . After reviewing articles that met inclusion criteria, we categorized the articles into 5 topical categories. Nineteen articles evaluated overdose prevention programs. These studies were largely observational in nature and included evaluations of programming. They also included 4 prospective cohort studies that followed participants over time. 18, [23] [24] [25] The next set of articles (n = 11) evaluated the effects of OEND programs on the experiences and attitudes of participants. These included qualitative (n = 4) and survey (n = 7) studies. Four articles described willingness of medical providers to prescribe naloxone. Five studies compared routes of naloxone administration in prehospital settings. In this category were 4 prospective studies, of which 2 were observed cohorts and 2 were randomized trials. Finally, 2 studies evaluated the cost-effectiveness of naloxone. The following results summarize our findings.
Evaluation of Overdose Education and Naloxone Distribution Programs
Community-based organizations and a number of state public health departments began conducting and sponsoring OEND programs in 1996.
11 OEND programs typically make naloxone directly available to people who use opioids, outside of a medical setting, and include training on opioid overdose prevention, recognition, and response. The overdose response training includes seeking help from the emergency medical system, rescue breathing, administering naloxone, and staying with the victim until recovery or help arrives.
The articles representing program evaluations of OEND programs in Table 1 suggests that mortality from overdose can be prevented by providing overdose education and naloxone to a variety of participants, including people who used needle exchange programs and injected heroin, 18, 23, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] people using pharmaceutical opioids, 37, 38 people who use opioids in treatment, 24, 25 and the family and friends of people who use drugs. 39, 40 These studies demonstrated that OEND trainings improved participants' knowledge of opioid overdoses and equipped them to administer naloxone safely and effectively when witnessing an overdose. One study suggested that participants reduced their frequency of injecting drugs and were more likely to enter treatment 6 months after naloxone training compared with baseline. 35 In Chicago, overdose deaths were reduced after the introduction of the OEND program. 33 An analysis that compared communities in Massachusetts with no OEND implementation with those with low implementation (1-100 people trained per 100,000 population) and high implementation (greater than 100 people trained per 100,000 population) demonstrated 27% and 46% reductions in opioid overdose mortality rates, respectively, after adjusting for community-level demographic and substance use factors. 40 
Effects of OEND Programs on Experiences and Attitudes of Participants
A number of articles support the feasibility of OEND programs. One concern that may inhibit naloxone prescribing is that potential bystanders or witnesses may not wish to intervene in response to an overdose. Several studies confirm that witnesses are willing to take action to revive victims. 19, [41] [42] [43] [44] One study of people who use heroin showed that nearly every participant was willing to administer naloxone and perform rescue breathing if they had been trained. 45 The majority of participants from a needle exchange program who used heroin (92%) in an Australian study also reported a willingness to participate in an OEND program. Other studies assessed the willingness of participants to have naloxone used on them in an overdose event, with most participants responding that they would want naloxone to be administered to them in an overdose. 46 Because naloxone must be administered by a bystander, concerns that lay bystanders cannot accurately identify an opioid over- dose and properly administer naloxone have been raised. 47 Several studies suggest that bystanders, including people who use opioids, are capable of recognizing an opioid overdose and administering naloxone. 48, 49 In addition to targeting people who use opioids, some OEND programs focus on educating family members and/or bystanders who may witness an opioid overdose. 50 An evaluation of 6 OEND programs concluded that trained participants were more likely to recognize overdose scenarios and identify when naloxone administration was indicated compared with those who had not received training. 49 Trained respondents scored similarly to medical experts in accurately recognizing overdose scenarios and identifying instances when naloxone was indicated. 49 In a prospective study of overdose training and naloxone provision in 239 people who use opioids, participants had significant improvements in their knowledge of the risk factors for overdose, characteristics of an overdose, and the appropriate actions to reverse a potentially fatal overdose. 24 In Massachusetts, where a state-sponsored OEND program has been in existence since 2007, methadone maintenance and medically supervised withdrawal (inpatient detoxification) patients have been successfully trained in overdose prevention, equipped with naloxone rescue kits, and rescued people in the community. 37 One study investigated the ability of participants to accurately share information about overdose prevention and naloxone administration with their peers and family, finding that they were able to successfully diffuse information from the program to others. 51 Naloxone may be particularly beneficial in populations that may avoid or delay calling for emergency services (e.g., 911) when they witness an overdose due to fear of arrest for heroin or opioid analgesic possession, a preexisting warrant, or because they are afraid of jeopardizing their housing. 45, 52 Although overdose education typically includes instruction on calling emergency services, trained bystanders may feel more capable to handle an overdose without help from paramedics or medical personnel. A survey of prospective OEND trainees in Baltimore reported that fewer subjects would call for help after naloxone training. 53 These concerns may be reduced through legislation and collaboration with law enforcement to shield bystanders from legal consequences when calling 911 or administering naloxone. 35 
Medical Providers' Willingness to Prescribe Naloxone
Prescribers in general medical practice have limited experience regarding naloxone for take-home use and potential misconceptions about naloxone. In one study of 571 physicians conducted from 2002 to 2003, 23% of those surveyed were aware of the option of prescribing take-home naloxone as an intervention to prevent the development of overdose symptoms in people who use injection drugs. 54 Most physicians (54%) indicated that they would never consider prescribing naloxone to a patient who injected drugs, suggesting that providers may either be uncomfortable or lack knowledge about providing care for these patients. 54 These data were collected before pharmaceutical opioid overdose rates rapidly increased and community programs were well known, and did not assess physicians' willingness to prescribe naloxone to patients receiving prescription opioids. In another study conducted from 2001 to 2003, one third of 363 nurse practitioners, physicians, and physician assistants surveyed said they would consider prescribing naloxone. 55 In a recent investigation of 10 SUBSTANCE ABUSE medical provider attitudes towards prescribing naloxone, providers expressed concerns that naloxone may condone riskier drug use. 56 
Studies Comparing Routes of Naloxone Administration in Prehospital Settings
The intranasal route of administration is not currently FDA approved, but its safety, convenience, and effectiveness (compared with IM naloxone) has been reported in controlled trials in prehospital settings. [57] [58] [59] [60] [61] [62] IN naloxone is available for off-label use and is the local standard of care in many emergency departments. 62 In a study of people who used heroin, researchers reported a preference for IN naloxone administration over naloxone administered by needle injection due to its ease of use, reduced risk of blood-borne viruses, and less pain and risk from needle injection. 41 In a study of adverse events after IM and IV naloxone treatment, by paramedics, the most common adverse events in 1192 overdose episodes were withdrawal-related, including gastrointestinal discomfort, physical aggressiveness, tachycardia, shivering, sweating, tremors, confusion, and restlessness. 63 Overall, only 0.3% of patients were hospitalized for adverse events related to the administration of naloxone. Another study of 155 participants administered IM (n = 71) or IN (n = 84) naloxone involved no major adverse events. 59 Other studies have shown that although there is a longer mean response time and an additional dose of naloxone required when using IN naloxone, there were no additional adverse outcomes associated with its use.
59,64,65
Cost-Effectiveness
Two studies, one in the United States and one in Russia, estimated the cost-effectiveness of distributing naloxone to people who use heroin and concluded that naloxone distribution is costeffective.
66,67
DISCUSSION
Existing research suggests that training people who are at risk for overdose and their peers is a feasible and effective way to prevent mortality from overdose. The articles included in this review indicate that people are willing to be trained about the risk factors for an overdose and are capable of responding appropriately when witnessing an overdose. Both IM and IN naloxone have been shown to be effective at reversing an overdose in prehospital settings without considerable risks of adverse outcomes.
Some of the issues of implementing OEND programming into wider settings include medical providers' reluctance to prescribe naloxone. Medical providers may be concerned about bystanders ability to accurately recognize an overdose and administer naloxone, 47 the cost of naloxone to patients, 11 and condoning riskier drug use. 56 Legal concerns may also be part of the reason for low engagement of prescribers in overdose education and naloxone prescription. 68 In a legal review of naloxone prescribing, Burris et al. concluded that if medical providers prescribe naloxone to people who use opioids, they are doing so in a way that is consistent with state and federal laws regulating drug prescribing and the risks of malpractice are very low. 69 Between 2001 and 2013, 24 states and the District of Columbia (DC) enacted laws promoting the accessibility of naloxone in the community through limiting liability for prescribing, possessing, and/or administering naloxone. 70 Twenty-one of these states enacted laws promoting the prescription of naloxone to third parties, meaning those who are not themselves at risk for overdose but may be in such a person's social network. In the absence of special legislation or standing orders permitting third-party prescribing, providing naloxone to people who are not themselves at risk of overdose but who may be friends or family of people who use opioids might be outside of the prescriber-patient relationship. 69 Concerns about police involvement may prevent individuals with criminal justice involvement or using who are nonprescription opioids from carrying prescribed naloxone with them and/or calling emergency services during an overdose. 25, 31 Further regulatory or legislative action and community education/outreach to inform the public about their protections related to calling emergency services or administering naloxone may be necessary. 71 States increasingly recognize the importance of bystanders' responding to overdose and are providing some immunity from arrest and/or prosecution for drug possession crimes and/or liability protection for administering naloxone. 69 Twenty-one states and the District of Columbia have enacted "Good Samaritan" provisions providing some protection from prosecution for people who provide help at the scene of an overdose. 70 The potential absence of medical personnel at naloxone reversals has led some to express concern that individuals who have been revived from overdose outside of a medical setting have less opportunity to enter substance use treatment. 72 Advocates for naloxone distribution respond that it is an intervention that prevents death and allows for future possibility of recovery. 73 One study suggested that education may promote treatment entry. 35 Further work is needed about whether OEND or administration of naloxone increases treatment admissions for the individual trained or the person who overdosed. 35 Another common concern is that people may use larger doses of opioids, believing they can be rescued from an overdose, but this is unlikely because of the unpleasant effects of naloxone on opioid-dependent individuals, who rapidly experience symptoms of withdrawal with naloxone administration. 74 
Implications for Medical Practice
In 2012, the American Medical Association and Massachusetts Medical Society issued endorsements of OEND programs. 75 Recently, OEND programs have expanded access to naloxone in many states, but a number of states with high drug overdose death rates remain without OEND programs. 11 Furthermore, OEND programs were originally established to address overdose people who inject heroin, but many others are at risk, including people who take pharmaceutical opioids for pain. Additional risk groups have since been proposed as potential targets of overdose education and naloxone distribution (see Table 2 ).
Although not addressed in the studies identified by this review, rising rates of pharmaceutical opioid use and overdose require novel prevention approaches to reduce risk. These approaches could include co-prescription of naloxone with opioids, insurance reimbursement for take-home naloxone, pharmacy dispensing of naloxone without a prescription, and over-the-counter naloxone distribution. 13 More broadly, these interventions could be considered within the context of other opioid safety efforts, such as safe disposal 10 . Have ever been in drug treatment 100 11. Unstably housed or homeless 29 12. Concurrent use of opioids with alcohol, benzodiazepines, or antidepressants 84, 95, 101 of excess opioids, 38 prescription drug monitoring programs, 76 risk evaluation and mitigation strategies (REMS), 77 and abuse-deterrent medications. 78 New administration devices, such as Evzio, an autoinjector device, which was fast-tracked for approval by the FDA because of the severity of the opioid overdose epidemic, should be evaluated further for its effectiveness in prehospital settings and its limitations, such as cost and availability. 79 Opioid prescribers have a responsibility to assess the overdose risk in their patients and educate them about potential adverse events, including overdose. 80 Physicians have an opportunity to apply their clinical assessment skills to identify patients as candidates for overdose education and naloxone prescription based on known risk factors for overdose. A thorough clinical history would include asking patients about a history of prior overdose, chronic medical illness (pulmonary, renal, or hepatic disease), drug use, incarceration history, and use of other sedating medications. Key elements of counseling patients may include not taking more milligrams or more frequently than prescribed, self-monitoring of functional status while on opioids, and letting others in one's family or social network know about the risks of overdose and what to do in the event of an overdose (e.g., calling 911). Prescribers should consider advising patients to secure opioids and other sedating medications, such as benzodiazepines, by keeping them locked up in the home to avoid diversion and to avoid sharing medications. 80 For patients with overdose risk, medical providers should prepare patients with instructions to follow in the event of an overdose. Prescribing take-home naloxone could be part of this preparation. The prescribing of naloxone should not be seen as a discrete event, but as part of an ongoing process that includes patient education, monitoring, and opioid dose adjustment. 81 Because patients who have been prescribed naloxone are unable to use the drug on themselves, their peers and family members must be involved in overdose education and management training. 73 Barriers to prescribing naloxone may need to be overcome through efforts by physicians, pharmacists, policy-makers, patient advocates, and health care systems. Pharmacies should consider stocking naloxone, intramuscular needles or nasal atomizers, and educational materials on administration. Patients may have to pay out-of-pocket for naloxone until insurance companies and public payers (e.g., Medicaid) cover naloxone, administration devices, and associated counseling/education costs. The Appendix includes several Web resources produced by a variety of community-based OEND programs, government agencies, researchers, and activists that currently aim to educate medical providers about their patients' risk of opioid overdose and provide information about prescribing naloxone (see Supplemental Material). This list is not intended to be all inclusive or exhaustive but provides a sample of resources available for medical providers interested in prescribing naloxone.
Gaps Identified and Further Research Needs
Based on current available evidence, prescribers should consider providing overdose education and naloxone in medical practice. Further study of barriers and facilitators to OEND in conventional clinical settings with more diverse populations of people at risk for overdose is needed. Future research should investigate how to select patients for naloxone prescription, how to engage patients and potential bystanders in overdose education and management training, the optimal breadth and depth of overdose education, the proper roles for different health care team members in disseminating OEND, the safety of take-home naloxone across a broad range of patient characteristics, and the reach and effectiveness of overdose education and naloxone prescription in traditional health care settings. These issues are particularly important because OEND programs may not meet the needs of all people who use pharmaceutical opioids due to the limited geographic availability of OEND programs, stigma against accessing community-based OEND programs, which have traditionally served people who use heroin and people who inject drugs, and costs of naloxone and related counseling or educational services. Access through traditional medical and pharmacy settings may offer some advantages, including scale and insurance coverage. At the same time, clinical settings may not offer the degree of training or sensitivity to the needs of populations at risk demonstrated in dedicated community-based programs. Additionally, more research should be conducted to understand what may be limiting medical providers' willingness to prescribe naloxone. Finally, more research using empirical data is needed to examine the cost-effectiveness of providing naloxone to patients treated with pharmaceutical opioids. Although overdose education and naloxone distribution may be a key component of a public health effort to reduce opioid overdose deaths, our findings suggests that further research is needed on the role of naloxone in conventional medical practice. Medical providers are in an ideal position to prescribe takehome naloxone to reduce mortality for opioid overdose amongst their patients.
14 Data from observational, health services, and randomized controlled trials could further inform physician practice and establish a new standard of care, with regards to naloxone prescription to patients receiving opioids in medical practice settings. 
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